Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo. 2010

Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
Division of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.

OBJECTIVE Overexpression of phosphatase of regenerating liver-3 (PRL-3) has been implicated in tumor progression and metastasis of gastric carcinoma. Here we examined what alterations occur in the phenotype of gastric cancer cells in vitro and in vivo when PRL-3 expression is knocked down. METHODS We constructed a small interfering RNA (siRNA)-expressing vector which stably interfered with PRL-3 expression and was transfected into SH101-P4 cells, which express the highest PRL-3 mRNA levels among 13 gastric cancer cell lines. The new SH101-P4 subclones, in which PRL-3 was stably reduced, were established and their in vitro growth, motility and abilities of liver metastasis from the injected spleen were analyzed in vivo. RESULTS PRL-3 knockdown effectively suppressed invasion and growth of SH101-P4 cells in vitro. Liver metastasis in vivo was significantly decreased when PRL-3 expression was suppressed. The primary tumor size in the injected spleen tended to be smaller in PRL-3 knockdown clones than in the controls. These findings suggest that PRL-3 expression may contribute not only to the establishment of metastasis but also to the growth of primary foci of human gastric cancer. Therefore, PRL-3 may be one of the target molecules in gastric cancer therapy.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
December 2017, Archives of gynecology and obstetrics,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2015, Drug design, development and therapy,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
December 2016, Oncotarget,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
April 1995, International journal of cancer,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
August 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
June 2014, Journal of gastroenterology,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
March 2012, Molecular cancer therapeutics,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
October 2011, Cancer science,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2018, OncoTargets and therapy,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Yu-Ichiro Koma, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2018, Oncology research,
Copied contents to your clipboard!